ABSTRAK
Tesis ini menilai efikasi dan toksisiti Erlotinib/Gefitinib sebagai terapi lini kedua pada pasien KPKBSK yang mengalami progresifitas. Ini adalah sebuah penelitiankohor retrospektif antara tahun 2009 sampai 2013 dari rekam medis pasienKPKBSK yang mengalami progresifitas. Respons (subjektif, semisubjektif danobjektif) dievaluasi setiap bulan. Toksisiti dinilai setiap minggu sejak pemberianErlotinib/Gefitinib berdasarkan kriteria WHO. Hasil evaluasi respons objektif,tidak ada pasien yang memberikan respons komplit. Best overall response ratedari 31 pasien, 48,8% menetap, 22,6% perburukan,12,9% respons sebagian dan6,5% tidak dinilai/inevaluable. Pada penilaian respons semisubjektif didapatkan19.4% peningkatan berat badan, 51,6% penurunan berat badan dan 29,0%menetap. Waktu tengah tahan hidup mencapai 18 bulan, rerata masa tahan hidup1 tahunan 80,6% dan masa tahan hidup keseluruhan 6,50%. Data menunjukkantidak ada timbul toksisiti hematologi berat (grade ¾) dan data penilaian toksisitinon hematologi sangat jarang timbul toksisiti berat (grade ¾). Efikasi monoterapiEGFR-TKI (Erlotinib/Gefitinib) cukup tinggi dengan toksisiti yang ditimbulkantidak berat. Dengan demikian Erlotinib/Gefitinib sebagai terapi lini kedua cukupbaik.ABSTRACT This thesis assesses the efficacy and toxicity of Erlotinib/Gefitinib as a second line therapy in NSCLC patients. This is a retrospective cohort study between 2009and 2013 from the medical records of patients who experienced progressionNSCLC. Therapeutic response was evaluated every month. Toxicity assessedevery month since giving Erlotinib/Gefitinib according to WHO?s criteria. Resultsof objective response evaluation none of the patients complete response. Bestoverall response rate of 31 patients with the most stable response are 48.8%. Mostsemisubjective response obtained are 51.6% weight loss. The middle survival timereached 18 month, the mean 1 year survival time are 80.6% and a 6.50% overallsurvival. The data showed no hematologic toxicity arise severe (grade ¾) andnon-hematological toxicity very rarely arise severe toxicity. The efficacy of EGFRTKI monotherapy (Erlotinib/Gefitinib) is high enough with toxicity cause notsevere. Thus Erlotinib/Gefitinib as second-line therapy is quite good. ;This thesis assesses the efficacy and toxicity of Erlotinib/Gefitinib as a second line therapy in NSCLC patients. This is a retrospective cohort study between 2009and 2013 from the medical records of patients who experienced progressionNSCLC. Therapeutic response was evaluated every month. Toxicity assessedevery month since giving Erlotinib/Gefitinib according to WHO?s criteria. Resultsof objective response evaluation none of the patients complete response. Bestoverall response rate of 31 patients with the most stable response are 48.8%. Mostsemisubjective response obtained are 51.6% weight loss. The middle survival timereached 18 month, the mean 1 year survival time are 80.6% and a 6.50% overallsurvival. The data showed no hematologic toxicity arise severe (grade ¾) andnon-hematological toxicity very rarely arise severe toxicity. The efficacy of EGFRTKI monotherapy (Erlotinib/Gefitinib) is high enough with toxicity cause notsevere. Thus Erlotinib/Gefitinib as second-line therapy is quite good. |
SP-Jamaluddin M.pdf :: Unduh